Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
The CTMX news page on Stock Titan aggregates recent coverage and official announcements related to CytomX Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company listed on the Nasdaq Global Select Market. CytomX reports that it is developing novel, conditionally activated, masked biologics based on its PROBODY® therapeutic platform, with a focus on cancer indications such as advanced colorectal cancer and advanced melanoma.
Visitors to this page can review news items that describe the progress of CytomX’s clinical programs, including updates on varsetatug masetecan (Varseta-M, formerly CX-2051), a masked EpCAM-directed antibody-drug conjugate with a topoisomerase-1 inhibitor payload, and CX-801, a masked interferon alpha-2b PROBODY® cytokine. Company press releases have discussed Phase 1 dose escalation and expansion activities, translational biomarker data, and plans for potential later-stage development in colorectal cancer and melanoma.
In addition to pipeline updates, CytomX news often includes financial results, business updates, and information about investor conference presentations. These items provide context on the company’s operating priorities, cash position, and interactions with the investment community. News releases also highlight research and collaboration activities involving its PROBODY® platform, such as work on T-cell engagers and cytokine-based approaches in partnership with other biopharmaceutical companies.
By following CTMX news, investors and researchers can monitor how CytomX describes the evolution of its PROBODY® technology, its clinical data disclosures, and its collaborations with partners including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. This page offers a centralized view of publicly released information that may be relevant to understanding the company’s development-stage oncology pipeline and corporate activities.
CytomX Therapeutics (Nasdaq: CTMX) has announced the initiation of a Phase 1 dose-escalation study for its investigational bispecific antibody, CX-904, targeting EGFR and CD3 on T cells. This study marks the sixth candidate from CytomX's Probody platform to enter clinical trials, emphasizing its commitment to innovative cancer therapies. The trial aims to improve therapeutic windows in treating solid tumors, leveraging conditionally activated T-cell engagement. Early preclinical models indicate promising potential, and trial results may address unmet needs in multiple tumor types.
CytomX Therapeutics reported significant progress in its clinical studies and financial results for Q1 2022. Patient enrollment in Arm A of the Phase 2 study for praluzatamab ravtansine in breast cancer is complete, with initial data expected in H2 2022. The CX-2029 study's enrollment for squamous non-small cell lung cancer is also complete, with updates anticipated in the same period. The company has $263 million in cash, while revenue increased to $17.1 million. R&D expenses rose to $30.6 million, reflecting ongoing clinical developments.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) will announce its first quarter 2022 financial results on May 5, 2022, after U.S. markets close. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and provide a corporate update. Interested parties can access the live webcast on the company’s Events and Presentations page. CytomX, a leader in conditionally activated oncology therapeutics, features a robust pipeline including investigational drugs for various cancer types.
CytomX Therapeutics (Nasdaq: CTMX) announced the impending retirement of John A. Scarlett, M.D. from its board, effective at the next annual stockholder meeting on June 15, 2022. Dr. Scarlett has been on the board since June 2016, contributing significantly to the company as chair of the Compensation Committee. CEO Sean McCarthy highlighted Dr. Scarlett's invaluable biopharma experience during his tenure. CytomX is focused on developing innovative oncology therapeutics, including investigational antibody-drug conjugates and immunotherapeutic candidates targeting difficult-to-treat cancers.
CytomX Therapeutics (CTMX) announced the retirement of Frederick W. Gluck from its board of directors, effective June 30, 2022. Gluck, a co-founder of the company, has been influential since its inception in 2008. His strategic insight has been key in positioning CytomX as a leader in oncology therapeutics. The board will remain robust with eight directors post-retirement, seven of whom are independent under NASDAQ rules. CytomX is recognized for its unique Probody technology, focusing on conditionally activated biologics aimed at improving cancer treatment outcomes.
CytomX Therapeutics (CTMX) announced that it will present preclinical data on its conditionally activated cytokine program at the AACR Annual Meeting from April 8-13, 2022. The data highlights the development of the interferon alpha-2b therapeutic candidate, which aims to enhance the effectiveness of immunotherapy while reducing toxicity. This initiative is part of CytomX's broader strategy to improve treatment options for patients with challenging cancers. The presentation is scheduled for April 11, 2022, and will focus on the therapeutic candidate's potential benefits.
CytomX Therapeutics reported its 2021 financial results on March 1, 2022, highlighting significant progress in its oncology pipeline. The company is advancing Phase 2 studies for praluzatamab ravtansine and CX-2029, with initial data expected in late 2022. Cash and investments totaled $305.2 million, down from $316.1 million in 2020. Total revenues fell to $69.6 million for 2021, primarily due to a $40 million milestone payment in 2020. R&D expenses increased to $114.2 million, reflecting greater clinical trial activity. CytomX is focused on executing its pipeline in 2022.
CytomX Therapeutics (Nasdaq: CTMX) will feature CEO Sean McCarthy in a virtual panel at the Cowen 42nd Annual Healthcare Conference on March 7, 2022, at 12:50 p.m. ET. The event will focus on conditionally activated oncology therapeutics.
Investors can access a live webcast via the CytomX website, with an archived replay available for 30 days post-event. The company is committed to innovating cancer treatments using its Probody technology platform, with ongoing Phase 2 studies targeting difficult-to-treat cancer types.
CytomX Therapeutics (CTMX) will report its fourth quarter and full year 2021 financial results on March 1, 2022, after U.S. market close. A conference call will follow at 5:00 p.m. ET to discuss results and provide updates. CytomX focuses on oncology therapeutics, notably through its Probody® technology. Its pipeline includes investigational drugs like praluzatamab ravtansine and CX-2029, both undergoing Phase 2 studies for advanced cancer types. Interested parties can access the conference call via the company’s website.
CytomX Therapeutics (CTMX) announced on February 16, 2022, the granting of stock options to nine new employees, totaling 189,400 shares at an exercise price of $4.08. This grant was made under the 2019 Employment Inducement Incentive Plan, approved in August 2020, aimed at attracting new talent. CytomX focuses on conditionally activated oncology therapeutics, with a pipeline that includes investigational therapies for challenging cancer types, including praluzatamab ravtansine and CX-2029, which are currently in Phase 2 clinical studies.
FAQ
What is the current stock price of Cytomx Therapeutics (CTMX)?
What is the market cap of Cytomx Therapeutics (CTMX)?
